MTA index: a simple 2D-method for assessing atrophy of the medial temporal lobe using clinically available neuroimaging

Manuel Menéndez-González1,2,3*, Alfonso López-Muñiz2,3, José A. Vega2, José M. Salas-Pacheco4 and Oscar Arias-Carrión5,6*

1 Unidad de Neurología, Hospital Álvarez-Buylla, Mieres, Spain
2 Departamento de Morfología y Biología Celular, Universidad de Oviedo, Oviedo, Spain
3 Instituto de Investigación Científica, Universidad Juárez del Estado de Durango, Durango, México
4 Instituto de Investigación Científica, Universidad Juárez del Estado de Durango, Durango, México
5 Unidad de Trastornos del Movimiento y Sueño (TMS), Hospital General Dr. Manuel Gea González/UNAM, México DF, Mexico
6 Unidad de Trastornos del Movimiento y Sueño (TMS), Hospital General Ajusco Medio, México DF, Mexico

Background and purpose: Despite a strong correlation to severity of AD pathology, the measurement of medial temporal lobe atrophy (MTA) is not being widely used in daily clinical practice as a criterion in the diagnosis of prodromal and probable AD. This is mainly because the methods available to date are sophisticated and difficult to implement for routine use in most hospitals—volumetric methods—or lack objectivity—visual rating scales. In this pilot study we aim to describe a new, simple and objective method for measuring the rate of MTA in relation to the global atrophy using clinically available neuroimaging and describe the rationale behind this method.

Description: This method consists of calculating a ratio with the area of 3 regions traced manually on one single coronal MRI slide at the level of the interpeduncular fossa: (1) the medial temporal lobe (MTL) region (A); (2) the parenchima within the medial temporal region, that includes the hippocampus and the parahippocampal gyrus—the fimbria taeania and plexus choroides are excluded—(B); and (3) the body of the ipsilateral lateral ventricle (C). Therefrom we can compute the ratio “Medial Temporal Atrophy index” at both sides as follows: \( MTA_i = \frac{(A - B)}{C} \).

Conclusions: The MTA index (MTAi) is a simple 2D-method for measuring the relative extent of atrophy in the MTL in relation to the global brain atrophy. This method can be useful for a more accurate diagnosis of AD in routine clinical practice. Further studies are needed to assess the usefulness of MTAi in the diagnosis of early AD, in tracking the progression of AD and in the differential diagnosis of AD with other dementias.

Keywords: medial temporal lobe atrophy, biomarker, Alzheimer, mild cognitive impairment, MRI, neuroimaging, diagnosis

BACKGROUND

Alzheimer’s disease’s (AD) pathology accumulates for years and may be even decades before it is typically diagnosed (Morris et al., 1996). Sensitive biomarker techniques may be able to pick up signs of neurodegeneration presymptomatically. Recently proposed criteria for research purposes for prodromal AD (Sperling et al., 2011), mild cognitive impairment (MCI) due to AD (Albert et al., 2011), and probable AD dementia (McKann et al., 2011) incorporate evidence of AD pathology including molecular changes and brain structure and function as supportive biomarkers. MRI-based biomarkers are among the supportive evidence for a diagnosis of early AD and MCI due to AD. By focusing on cortical regions known to be affected in AD dementia, subtle but reliable atrophy is identifiable in asymptomatic individuals nearly a decade before dementia, making this measure a potentially important imaging biomarker of early diagnosis (Dickerson et al., 2011). Volume losses in the medial temporal lobe (MTL) region—composed by the hippocampus and the parahippocampal gyrus—and posterior cingulated and orbitofrontal regions have been observed in AD and confirmed in many studies (Kesslak et al., 1991; Parnetti et al., 1996; Smith and Jobst, 1996; de Leon et al., 1997; Jack et al., 1997; Nagy et al., 1999; Bouwman et al., 2007; Eckerstrom et al., 2010; Jack et al., 2010; Zhang et al., 2010; Apostolova et al., 2012; Ewers et al., 2012; Leung et al., 2013; Heister et al.). This leads to a predictable pattern of brain atrophy that could be very useful to improve diagnosis and follow up and help making a better assessment of the neuroprotective effects of a therapy. The quantification of atrophy in the MTL (MTA) has been attempted using several different neuroimaging measurements, including rating scales, linear measurements, and volumetric methods.

Visual assessment rating scales are quick, and can be performed on large numbers of scans in a clinical setting, the disadvantage being that there is a loss of accuracy compared...
with objective analysis and are subjected to interrater variability (Westman et al., 2011). Some studies found that visual rating assessment of the MTL gave similar prediction accuracy to multivariate classification and manual hippocampal volumes (Ringman et al., 2010; Duara et al., 2013) while others reported the visual rating assessment failed to detect patients at high risk, such as people carrying mutations of familial AD and also failed to detect progression over time (Ridha et al., 2007; Pereira et al., 2013). In addition, clinical, demographic, and genetic variables can influence the classification of MTA cut-off scores, leading to misdiagnosis in some cases. These variables, in addition to the differential sensitivity and specificity of each cut-off, should be carefully considered when performing visual MTA assessment (Scheltens et al., 1992).

Linear measures of brain regions are easy to take using clinically available neuroimaging. Some studies attempted to define sentinel changes that will allow the use of linear measurements of the hippocampus or the temporal horn to support clinical decision making. These studies have yielded variable results, with sensitivities ranging from 33 to 93% and specificity of approximately 95% (Dahlbeck et al., 1991; Erkinjuntti et al., 1993; Frisoni et al., 2002).

Volumetric analysis provides an accurate and detailed measure of a predetermined circumscribed area or region of interest. For AD, the most used structure is the whole hippocampus. Some indices comparing the extent of atrophy in the hippocampus with the whole brain atrophy are also being described (http://brainatrophyindices.blogspot.com). Manual volumetry is considered the gold standard but it has some drawbacks. First it requires training since the tracer must learn to delineate the hippocampus’s boundaries and anterior- and posterior-limits. Then segmentation of the hippocampus takes approximately 20–30 min, depending on user experience (Soininen et al., 1994; Petrella et al., 2003), which limits routine clinical use. Some groups automated segmentation techniques and protocols for multi-atlas driven automatic segmentation of the hippocampus (Morra et al., 2008; Brewer et al., 2009; Kovacevic et al., 2009). Results of a study comparing manual and automated determination of hippocampal volumes in MCI and early AD indicated that these two methods derived highly correlated results with strong agreement (Shen et al., 2010). Albeit homogenization efforts are under development (Frisoni and Jack, 2011; Boccardi et al., 2013), the complexity and diversity of protocols used for volumetry keeps being a limitation today.

In summary, despite convenience and strong correlation to severity of AD pathology, MTA is not being used in daily clinical practice for diagnosing prodromal and probable AD yet, as it is in clinical trials and research studies. This is mainly because the methods already described lack accuracy (visual methods) or are not convenient enough to be routinely used by clinicians in busy departments (volumetric methods).

PURPOSE

In this report we aim to describe a new, objective and simple 2D-method for measuring atrophy of the MTL using clinically available neuroimaging. We also aim to explain the rationale behind this method. However, we do not seek to describe here the validity of this parameter for diagnosing AD since these researches are being conducted currently and results will be addressed in future publications.

PROTOCOL DESCRIPTION

This method consists of measuring the area of 3 brain regions on one single MRI slide and then use these data for calculating a simple ratio. First, we take the coronal slide at the level of the interpeduncular fossa on the TIR sequence. Then, regions are traced manually, simply using the pointer-rule tool of any software for visualizing DICOM images. As guidelines to draw structures and boundaries we followed the atlases by Mai et al. (1997) and Duvernoy (1998). The three areas are: (1) the MTL region (A), defined in a coronal brain slide as the four-sided space bordered in its inferior side by the tentorium cerebelli, in its medial side by the cerebral peduncles, in its upper side by the roof of the temporal horn of the lateral ventricle and in its lateral side by the collateral sulcus and a straight-line linking the collateral sulcus with the lateral edge of the temporal horn of the lateral ventricle; (2) the parenchima within the medial temporal region, that includes the hippocampus and the parahippocampal gyrus—–the fimbria taenia and plexus choroides are excluded—(B); and (3) the body of the ipsilateral lateral ventricle (C) (Figure 1). Therefrom, we can compute the ratio “Medial Temporal Atrophy index (MTAi)” at both sides as follows: \( MTAi = (A - B) \times 10/C \). An example is shown in Figure 2.

If we have two MRI studies from different times (first one, second one), we can also compute the yearly rate of MTA as follows: \( yrMTA = (A - B2) - (A1 - B1) \times 120/(\#\text{months between MRI studies}) \) and the yearly rate of relative MTA as follows: \( yrMTAr = (A - B2) - (A1 - B1) \times 120/(C2 - C1) \times (\#\text{months between MRI studies}) \).

EXPRESSING THE MEDIAL TEMPORAL ATROPHY INDEX

When we compute the MTAi we obtain 2 values, one for each hemisphere. In addition, it is also interesting to compute the median of these 2 values, and the index of asymmetry (IA). We determine the IA using formula \( IA = (MTAi - dMTAi)/(MTAi + dMTAi) \times 100 \). Small positive or negative IA values of magnitude less than \( \pm 3\% \) indicate that there is not a significant hemispheric asymmetry and the median MTAi can be used alone as a parameter of the global relative MTA. Higher IA values indicate significant hemispheric asymmetry and the median value should not be used alone since it is not a good representative value of the extent of relative MTA. Thus, the MTAi can be presented directly as the absolute right/left MTAi values or as the median MTAi with the IA (Table 1).

RATIONALE BEHIND THE MEDIAL TEMPORAL ATROPHY INDEX

The rationale behind this method is based on two premises: First, AD is a disease affecting the hippocampus, not a disease of the hippocampus. From a neuropathological point of view it is evident that that the characteristic pathological changes in AD begin outside the hippocampus, with development of neurofibrillary tangles in the transentorhinal and entorhinal cortex, spreading subsequently to the subiculum and CA1 regions of the
Menéndez-González et al. The MTA index

**FIGURE 1** | MRI from a patient with MCI with boundaries of the three areas needed for calculating the Medial Temporal Atrophy index (MTAi). The section passes through the interpeduncular fossae. The three areas are: (1) the medial temporal lobe region (A), defined in a coronal brain slide as the space bordered in its inferior side by the tentorium cerebelli, in its medial side by the cerebral peduncles, in its upper side by the roof of the temporal horn of the lateral ventricle and in its lateral side by the colateral sulcus and a straight-line linking the colateral sulcus with the lateral edge of the temporal horn of the lateral ventricle; (2) the parenchima within the medial temporal region, that includes the hippocampus and the parahippocampal gyrus (B); and (3) the body of the ipsilateral lateral ventricle (C).

**TABLE 1** | Mean of the mean Medial Temporal Atrophy index (mMTAi) and Index of Asymmetry (IA) values in short series of patients with MCI (3), mild AD (3), moderate AD (3), severe AD (3), FTLD -not staged- (3), LBD -not staged- (3) and 5 healthy controls. Values are merely illustrative -not informative-.

| Condition          | Mean mMTAi | Mean IA |
|--------------------|-------------|---------|
| Healthy control    | 2.4         | 1.8     |
| MCI                | 3.1         | 2.4     |
| Mild AD            | 4.6         | 2.6     |
| Moderate AD        | 5.2         | 2.8     |
| Severe AD          | 5.8         | 3.4     |
| FTLD               | 3.8         | 8.2     |
| DLB                | 2.7         | 3.7     |

**FIGURE 2** | Example of the Medial Temporal Atrophy index (MTAi) in a patient with mild AD. The three areas were traced manually on each hemisphere using the software for visualizing radiological images IMPAX. The data needed to compute the index are displayed automatically. We have underlined the different areas in colors as in Figure 1. The MTAi in the right hemisphere is: rMTAi = (326.5 – 201.4) x 10 / 189.7 = 6.59. The MTAi in the left hemisphere is: lMTAi = (326.5 – 224.0) x 10 / 175.2 = 5.85. Note how in spite of the coincidence of this case with exactly the same medial temporal region (A and A’) in both hemispheres, the right MTAi is clearly higher than the left MTAi. Indeed when we calculate the Index of Asymmetry (IA), it is higher than 3: IA = (5, 85 – 6.59) / (5, 85 + 6.59) x 100 = −5, 15%.

hippocampus (Jack et al., 1992; Braak and Braak, 1985; Convit et al., 2000; Kerchner et al., 2010; Lim et al., 2012) and later to limbic, and ultimately to neocortical regions, such as the precuneus, middle frontal gyrus, and posterior cingulate gyrus. The severity of this atrophy, at least in the medial temporal regions, correlates with the severity of underlying neuropathological changes seen on postmortem studies (Echávarri et al., 2011). The second premise is that, despite most volumetric methods focus on the hippocampus and disregard the parahippocampal gyrus, many studies have shown that parahippocampal atrophy is as good indicator of AD as the hippocampus atrophy is (Nestor et al., 2008; Burgmans et al., 2011; Smith et al., 2012; Zarei et al., 2012). Thus, the entorinal cortex, the hippocampus, and the parahippocampal gyrus may be considered as the “epicentrum” of the neurodegenerative process. Therefore, in order to pick up the disease early we do not need to find out the volume of the whole hippocampus but detect atrophy at “the point” where the pathology is visible first.

**THE SLICE SELECTED**

Functionally, the hippocampus can be segmented into three distinct anatomical and functional subregions (head, body, and tail), according to the morphology and relative connectivity with prefrontal cortex (PFC), posterior cingulate cortex (PCC), and thalamus, respectively. The AD group show stronger hippocampus–PFC and weaker hippocampus–PCC functional connectivity, the magnitudes of which correlate with cognitive performance (Convit et al., 2000; Dickerson et al., 2011; Libby et al., 2012). In line with this fact and in order to assess the body of the hippocampus we have taken the coronal section passing through the interpeduncular fossa where the body of the hippocampus can be clearly viewed. However, this index might be performed on any other coronal slide where the MTL structures are viewed.

**THE AREAS SELECTED**

Age-associated differences are detected in the MTL (Parnetti et al., 1996; Jack et al., 1997; Apostolova et al., 2012; Leung et al., 2013)
with an acceleration of MTA starting around 72 years of age in healthy people (Jack et al., 1997). However, these changes are modest and their rate of progression over time is relatively slow with a mean rate of about 1.6% per year (Leung et al., 2013). Accelerated MTA is a consistent finding in AD and MCI with rates of about 2.8% in stable MCI, 3.7% in MCI transitioning to AD (MCI progressors), and up to 4.0% in AD (Kesslak et al., 1991; Parnetti et al., 1996; Jack et al., 1997; Bouwman et al., 2007; Eckerstrom et al., 2010; Jack et al., 2010; Apostolova et al., 2012; Ewers et al., 2012; Leung et al., 2013; Heister et al.). Frontotemporal dementia may also lead to MTA, but in a different pattern: frontotemporal dementia and semantic dementia show atrophy in the anterior portion of the hippocampus, and in semantic dementia the atrophy is asymmetrical, with the left hippocampus being affected more severely. No significant hippocampal atrophy is detected in non-fluent progressive aphasia (Barber et al., 1999; Schacter and Wagner, 1999; Chan et al., 2001; van de Pol et al., 2006). Other diseases such as dementia with Lewy bodies do not show MTA or it is much milder (Hashimoto et al., 1998; Whitwell et al., 2007; Chou et al., 2010).

In contrast to MTA, ventricular enlargement (body of lateral ventricles) in old people lacks specificity representing a measure of global brain atrophy due to aging or any neurodegenerative disorder. Global ventricular enlargement correlates with decline in cognitive performance and with cerebrospinal fluid pathologic markers of AD (Thompson et al., 2004; Apostolova et al., 2010). Absolute ventricular volumes and ventricular enlargement are greater in subjects with AD and MCI compared to age-matched controls. Ventricular enlargement also demonstrated sensitivity to disease progression by way of discriminating between subjects with stable MCI and those that progressed to AD (Nestor et al., 2008). However, it is important to note that all these studies were made using absolute ventricular volumes, without differentiation among the different portions of the lateral ventricles, while the lateral (temporal) horns are the portion contributing most to the ventricular enlargement in early AD (Giesel et al., 2006). It is well-known that enlargement of lateral ventricles is a measure of unspecific global brain atrophy since it is strongly associated both with aging in healthy and with neurodegeneration (Apostolova et al., 2012). Almost any neurodegenerative disorder affecting the brain hemispheres leads to some degree of ventricular enlargement, including Parkinson's disease (Meyer et al., 2007; Apostolova et al., 2010; Dalaker et al., 2011), Lewy-Body Dementia (Meyer et al., 2007), Frontotemporal Lobe Dementia (Galton et al., 2001; Gordon et al., 2010), and Corticobasal Degeneration (Hauser et al., 1996) and so do some psychiatric conditions (Swayze et al., 1990; Mathalon et al., 2001). Thus, it would be interesting to compare the extent of atrophy in the MTL with the extent of global brain atrophy (Table 1).

THE RATIO

This index reflects the rate of atrophy in the MTL—that is a value rather specific of AD since its early stages—in relation to the global unspecific atrophy represented by ventricular enlargement. Thus, it is a measure estimative of the contribution of the atrophy in the MTL to the whole brain atrophy.

ADVANTAGES AND LIMITATIONS OF THE MTA INDEX

From the clinician's point of view, the MTA index has the following advantages over other methods: (1) Measurement and scoring of MTA index is objective and reliable, providing a distinct advantage over visual techniques. (2) Volumetric measurements require the use of special software, and much greater technical stringency in the acquisition of the MRI scans and are far more prone to a variety of measurement errors. Delineating the areas needed for calculating the MTA index is fast and easy; little training is needed. Therefore, it can be implemented for daily clinical practice using basic neuroimaging facilities currently available in most hospitals with busy clinical settings. (3) An additional advantage of using MTA index over volumetric measures is that regional brain volumes are variable across individuals and need to be normalized by conversion to a ratio of the absolute volumes to intracranial volume, whereas the MTA index has built-in normalization and thus avoids multiplicative errors inherent in using ratios of two quantitative variables. (4) The same way, as aging affects both the hippocampus and lateral ventricles independently of AD pathology, aging should be included as a covariate in methods providing absolute volumes or scores. The MTA index is an “intra-patient” ratio comparing the MTL and lateral ventricles, so it will probably not need cut-off scores adjusted by age. For the yearly rate of MTA and the yearly rate of relative MTA, normalization is not necessary neither because each subject serves as their own control.

On the other hand, the main limitation of the MTA index is that scoring is based on measurements performed on a single coronal slice, thereby providing a limited perspective of overall brain pathology. It is also expected that other conditions affecting the ventricular morphology, such as hydrocephalus, will probably alter the interpretation of the MTAi in these cases.

This paper is a methodological description only. Cut-off scores have to be calculated and its use as a parameter for diagnosing AD in research and clinical practice has to be validated. Particularly, prospective studies are needed to assess the usefulness of MTA index in the diagnosis of early AD, in tracking the progression of AD and in the differential diagnosis of AD with other dementias.

CONCLUSIONS

We report a new, manual method for assessing medial temporal lobe atrophy (MTA) that is objective and easy to apply using clinically available neuroimaging. It may have some advantages over visual and volumetric methods that still need to be evaluated.

REFERENCES

Albert M. S., Dekosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., et al. (2011). The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging and Alzheimer’s Association workgroup. Alzheimers Dement. 7, 270–279. doi: 10.1016/j.jalz.2011.03.008 Apostolova, L. G., Beyer, M., Green, A. E., Hwang, K. S., Morra, J. H., Chou, Y. Y., et al. (2010). Hippocampal, caudate, and ventricular changes in Parkinson’s disease with and without dementia. Mov. Disord. 25, 687–695. doi: 10.1002/mds.22799 Apostolova, L. G., Green, A. E., Babakchianian, S., Hwang, K. S., Chou, Y. Y., Toga, A. W., et al. (2012). Hippocampal atrophy and ventricular enlargement in normal aging, mild cognitive impairment (MCI), and Alzheimer disease. Alzheimer Dis. Assoc. Disord. 26, 17–27. doi: 10.1097/WAD.0b013e3182163662
